Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 5/2021

01.05.2021 | Breast Cancer (AS Zimmer, Section Editor)

Rare Breast Cancer Subtypes

verfasst von: Sarah Jenkins, Megan E. Kachur, Kamil Rechache, Justin M. Wells, Stanley Lipkowitz

Erschienen in: Current Oncology Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Breast cancer is a collection of diseases including the more common invasive ductal and lobular carcinomas and rarer subtypes of breast cancer. This review summarizes the features of rare breast cancers.

Recent Findings

Each of the rare tumors has defined pathological and clinical features that impact treatment recommendations. In this review, we summarize these for each rare type of breast cancer and where available we include molecular features of each tumor.

Summary

Rare subtypes of breast cancer each have unique features. In many cases, data is limited for the optimal treatment approaches.
Literatur
1.
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23(29):7350–60.PubMedCrossRef
2.
Sharpiro C, Barsky SH. Infiltrating carcinomas of the breast: not one disease. In: Bland KI, Copeland III EM, editors. The Breast: Comprehensive management of benign and malignant disease. 1. Philadelphia: Saunders Elsevier; 2009. p. 231–47.CrossRef
3.
•• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74 This landmark paper identified molecular subtypes of breast cancer including luminal A, luminal B, basal, and HER2 enriched based on the gene expression patterns, and is the basis for preclinical and clinical trial approaches to breast cancer.PubMedPubMedCentralCrossRef
4.
•• WHO Classification of Tumours Editorial Board. Breast Tumours: World Health Organization classification of tumours. 5th ed. Lyon, France: IARC Press; 2019. The WHO classification of breast cancer is the reference for all pathology analysis and classification.
5.
Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7.PubMedCrossRef
6.
Marrazzo E, Frusone F, Milana F, Sagona A, Gatzemeier W, Barbieri E, et al. Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020;49:87–92.PubMedCrossRef
7.
Nakata B, Kuroda K, Yoshida Y, Iimori N, Masuda G, Lee T, et al. Huge mucinous carcinoma of the breast in which doubling time was observed by computed tomography during 3 years without treatment. Breast Dis. 2018;37(4):215–8.PubMedCrossRef
8.
Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ, Yang JH. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 2011;14(4):308–13.PubMedPubMedCentralCrossRef
9.
Kim HS, Lee JU, Yoo TK, Chae BJ, Son D, Kim YJ, et al. Omission of chemotherapy for the treatment of mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society. J Breast Cancer. 2019;22(4):599–612.PubMedPubMedCentralCrossRef
10.
Limaiem F, Mlika M. Tubular breast carcinoma. Treasure Island (FL): StatPearls; 2020.
11.
Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.PubMedCrossRef
12.
McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol. 1982;6(5):401–11.PubMedCrossRef
13.
Javid SH, Smith BL, Mayer E, Bellon J, Murphy CD, Lipsitz S, et al. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg. 2009;197(5):674–7.PubMedCrossRef
14.
Sun JY, Zhou J, Zhang WW, Li FY, He ZY, Wu SG. Tubular carcinomas of the breast: an epidemiologic study. Future Oncol. 2018;14(29):3037–47.PubMedCrossRef
15.
Romano AM, Wages NA, Smolkin M, Fortune KL, Atkins K, Dillon PM. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification. Breast Dis. 2015;35(2):103–11.PubMedCrossRef
16.
Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ. Invasive cribriform carcinoma of the breast. Histopathology. 1983;7(4):525–36.PubMedCrossRef
17.
Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM. Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast: a SEER population-based study. Medicine (Baltimore). 2015;94(31):e1309.PubMedPubMedCentralCrossRef
18.
Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. Hum Pathol. 1990;21(3):333–8.PubMedCrossRef
19.
Zhang W, Zhang T, Lin Z, Zhang X, Liu F, Wang Y, et al. Invasive cribriform carcinoma in a Chinese population: comparison with low-grade invasive ductal carcinoma-not otherwise specified. Int J Clin Exp Pathol. 2013;6(3):445–57.PubMedPubMedCentral
20.
Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thurlimann B, et al. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol. 2015;26(12):2442–9.PubMedPubMedCentralCrossRef
21.
Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Ann Oncol. 2012;23(6):1428–36.PubMedCrossRef
22.
Colleoni M, Russo L, Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast. 2011;20(Suppl 3):S153–7.PubMedCrossRef
23.
Suh YJ, Shin H, Kwon TJ. Natural history of invasive papillary breast carcinoma followed for 10 years: a case report and literature review. Case Rep Med. 2017;2017:3725391.PubMedPubMedCentralCrossRef
24.
Zheng YZ, Hu X, Shao ZM. Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: a SEER population-based study. Sci Rep. 2016;6:24037.PubMedPubMedCentralCrossRef
25.
Liu ZY, Liu N, Wang YH, Yang CC, Zhang J, Lv SH, et al. Clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast: a large case study. J Cancer Res Clin Oncol. 2013;139(1):77–84.PubMedCrossRef
26.
Fakhreddine MH, Haque W, Ahmed A, Schwartz MR, Farach AM, Paulino AC, et al. Prognostic factors, treatment, and outcomes in early stage, invasive papillary breast cancer: a SEER investigation of less aggressive treatment in a favorable histology. Am J Clin Oncol. 2018;41(6):532–7.PubMedCrossRef
27.
Saita C, Goto R, Aruga T, Idera N, Honda Y, Horiguchi K, et al. Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved. BMC Res Notes. 2016;9:46.PubMedPubMedCentralCrossRef
28.
Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, et al. Histologic heterogeneity of triple negative breast cancer: a National Cancer Centre Database analysis. Eur J Cancer. 2018;98:48–58.PubMedCrossRef
29.
Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys. 2005;62(4):1040–7.PubMedCrossRef
30.
Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol. 2010;23(10):1357–63.PubMedCrossRef
31.
de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind'homme B, Martin E, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91(7):641–3.PubMedCrossRef
32.
Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9(2):R24.PubMedPubMedCentralCrossRef
33.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997;349(9064):1505-10.
34.
Foschini MP, Eusebi V. Rare (new) entities of the breast and medullary carcinoma. Pathology. 2009;41(1):48–56.PubMedCrossRef
35.
Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40(4):1365–85.PubMedCrossRef
36.
Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist. 2014;19(8):805–13.PubMedPubMedCentralCrossRef
37.
Eichhorn JH. Medullary carcinoma, provocative now as then. Semin Diagn Pathol. 2004;21(1):65–73.PubMedCrossRef
38.
Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res. 1990;5(11):1113–9.PubMedCrossRef
39.
Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manie E, et al. Medullary breast carcinoma, a triple-negative breast cancer associated with BCLG overexpression. Am J Pathol. 2018;188(10):2378–91.PubMedCrossRef
40.
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.PubMedCrossRef
41.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef
42.
Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, et al. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat. 2016;157(1):117–31.PubMedPubMedCentralCrossRef
43.
Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer. 2009;45(10):1780–7.PubMedCrossRef
44.
Mills AM. C EG, S MW, C MB, Atkins KA. Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. Am J Surg Pathol. 2016;40(8):1109–16.PubMedCrossRef
45.
Yamazaki M, Nagata Y, Monji S, Shigematsu Y, Baba T, Shimokawa H, et al. Apocrine carcinoma of the breast. J UOEH. 2011;33(4):293–301.PubMedCrossRef
46.
Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28(11):1393–409.PubMed
47.
Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, et al. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res. 2010;12(4):R63.PubMedPubMedCentralCrossRef
48.
Sun X, Zuo K, Yao Q, Zhou S, Shui R, Xu X, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol. 2020;33:2473–82.PubMedCrossRef
49.
Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol. 2001;158(1):207–14.PubMedPubMedCentralCrossRef
50.
Wu W, Wu M, Peng G, Shi D, Zhang J. Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study. Cancer Med. 2019;8(18):7523–31.PubMedPubMedCentralCrossRef
51.
Arciero CA, Diehl AH, 3rd, Liu Y, Sun Q, Gillespie T, Li X, et al. Triple-negative apocrine carcinoma: a rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020.
52.•
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–8. This reference and the following one demonstrate the activity of anti-androgen therapy in apocrine TNBC.
53.•
Jongen L, Paridaens R, Floris G, Wildiers H, Neven P. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. Breast Cancer Res Treat. 2016;155(3):603–7. This reference and the one above demonstrate activity of anti-androgen therapy in apocrine TNBC.
54.
• Rosen PP, Ernsberger D. Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma. Am J Surg Pathol. 1987;11(5):351–8 This paper defines this rare cancer subtype.PubMedCrossRef
55.
Denley H, Pinder SE, Tan PH, Sim CS, Brown R, Barker T, et al. Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. Histopathology. 2000;36(3):203–9.PubMedCrossRef
56.
Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL. Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. Mod Pathol. 2003;16(9):893–901.PubMedCrossRef
57.
Rakha EA, Badve S, Eusebi V, Reis-Filho JS, Fox SB, Dabbs DJ, et al. Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology. 2016;68(1):45–56.PubMedPubMedCentralCrossRef
58.
Bataillon G, Fuhrmann L, Girard E, Menet E, Lae M, Capovilla M, et al. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. Histopathology. 2018;73(2):273–83.PubMedCrossRef
59.
Soo K, Tan PH. Low-grade adenosquamous carcinoma of the breast. J Clin Pathol. 2013;66(6):506–11.PubMedCrossRef
60.
• Van Hoeven KH, Drudis T, Cranor ML, Erlandson RA, Rosen PP. Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol. 1993;17(3):248–58 This paper is the largest clinicopathologic study of this rare tumor subtype.PubMedCrossRef
61.
Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, et al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology. 2019;75(2):213–24.PubMedPubMedCentralCrossRef
62.
Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3):350–3.PubMedCrossRef
63.
Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016;113(7):721–5.PubMedCrossRef
64.
Li D, Xiao X, Yang W, Shui R, Tu X, Lu H, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567–75.PubMedCrossRef
65.
• Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–76 This work identifies the ETV6-NTRK3 fusion gene and protein as a nearly universal driver mutation in secretory breast carcinoma.PubMedCrossRef
66.
Roviello G, D'Angelo A, Sciortino M, Mini E, Nobili S, De Logu F, et al. TRK fusion positive cancers: from first clinical data of a TRK inhibitor to future directions. Crit Rev Oncol Hematol. 2020;152:103011.PubMedCrossRef
67.
Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11(10):1343–7.PubMedCrossRef
68.
Krausz T, Jenkins D, Grontoft O, Pollock DJ, Azzopardi JG. Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis. Histopathology. 1989;14(1):25–36.PubMedCrossRef
69.
Al-Baimani K, Bazzarelli A, Clemons M, Robertson SJ, Addison C, Arnaout A. Invasive pleomorphic lobular carcinoma of the breast: pathologic, clinical, and therapeutic considerations. Clin Breast Cancer. 2015;15(6):421–5.PubMedCrossRef
70.
Butler D, Rosa M. Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Arch Pathol Lab Med. 2013;137(11):1688–92.PubMedCrossRef
71.
Cha YJ, Kim YH, Cho NH, Koo JS. Expression of autophagy related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. Int J Clin Exp Pathol. 2014;7(6):3389–98.PubMedPubMedCentral
72.
Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology. 2004;44(4):332–8.PubMedCrossRef
73.
Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature. Ann Diagn Pathol. 2012;16(3):185–9.PubMedCrossRef
74.
Haque W, Arms A, Verma V, Hatch S, Brian Butler E, Teh BS. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. Breast. 2019;43:67–73.PubMedCrossRef
75.
Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol. 2008;98(5):314–7.PubMedCrossRef
76.
Jung SP, Lee SK, Kim S, Choi MY, Bae SY, Kim J, et al. Invasive pleomorphic lobular carcinoma of the breast: clinicopathologic characteristics and prognosis compared with invasive ductal carcinoma. J Breast Cancer. 2012;15(3):313–9.PubMedPubMedCentralCrossRef
77.
Liu YL, Choi C, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, et al. Invasive lobular breast carcinoma: pleomorphic versus classical subtype, associations and prognosis. Clin Breast Cancer. 2018;18(2):114–20.PubMedCrossRef
78.
Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An analysis of oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J. 2017;23(6):677–86.PubMedCrossRef
79.
Mahtani RL, Vogel CL. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint? J Clin Oncol. 2008;26(35):5823–4.PubMedCrossRef
80.
Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018;18(8):485–99.PubMedCrossRef
81.
• Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23 This paper presents an international consensus for the diagnosis and treatment of inflammatory breast cancer.PubMedCrossRef
82.
van Uden DJP, van Maaren MC, Strobbe LJA, Bult P, van der Hoeven JJ, Siesling S, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res. 2019;21(1):113.PubMedPubMedCentralCrossRef
83.
Wu SG, Zhang WW, Wang J, Dong Y, Sun JY, Chen YX, et al. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study. Future Oncol. 2019;15(5):507–16.PubMedCrossRef
84.
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82(12):2366–72.PubMedCrossRef
85.
Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.PubMedCrossRef
86.
Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244–59.PubMedCrossRef
87.
Cooper CL, Karim RZ, Selinger C, Carmalt H, Lee CS, O'Toole SA. Molecular alterations in metaplastic breast carcinoma. J Clin Pathol. 2013;66(6):522–8.PubMedCrossRef
88.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO classification of tumours of the breast. Lyon: IARC Press; 2012.
89.
Leddy R, Irshad A, Rumboldt T, Cluver A, Campbell A, Ackerman S. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features. J Clin Imaging Sci. 2012;2:21.PubMedPubMedCentralCrossRef
90.
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73.PubMedCrossRef
91.
Verma S, Cimino-Mathews A, Figueroa Magalhaes MC, Zhang Z, Stearns V, Connolly RM. A clinicopathologica analysis of 45 patients with metaplastic breast cancer. Cancer Res. 2012;72(24 suppl):527s.
92.
Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17(4):605–13.PubMedCrossRef
93.
Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289–95.PubMedCrossRef
94.
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005;7(6):R1028–35.PubMedPubMedCentralCrossRef
95.
Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49(1):10–21.PubMedCrossRef
96.
Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB) - a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013;22:968–73.PubMedCrossRef
97.
Jia Y, He C, Liu L, Sun L, Chen Y, Luo Y, et al. A retrospective study of the imaging and pathological features of metaplastic breast carcinoma and review of the literature. Med Sci Monit. 2019;25:248–58.PubMedPubMedCentralCrossRef
98.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471–8.PubMedCrossRef
99.
Barnes PJ, Boutilier R, Chiasson D, Rayson D. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat. 2005;91(2):173–8.PubMedCrossRef
100.
Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273–80.PubMedCrossRef
101.
• Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209(4):445–53 This work domonstrates EGFR amplification, a potentially targetable abnormality, in ~25% of metaplastic breast cancer.PubMedCrossRef
102.
• Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–24 This work domonstrates PIK3CA activating mutations in a subset of metaplastic breast cancer.PubMedPubMedCentralCrossRef
103.
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
104.
Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol. 2004;204(2):131–9.PubMedCrossRef
105.
Krings G, Chen YY. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Mod Pathol. 2018;31(11):1661–74.PubMedCrossRef
106.
Amini A, Kakkis J, Reitherman R, Ibarra J, Sanati H. Near-complete pathological response with preoperative chemotherapy in a patient with metaplastic breast carcinoma. Anticancer Drugs. 2013;24(7):765–8.PubMedCrossRef
107.
Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130(1):345–51.PubMedCrossRef
108.
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9.PubMedCrossRef
109.
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.PubMedCrossRef
110.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef
111.
Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009;27(28):4693–700.PubMedCrossRef
112.
Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174–81.PubMedPubMedCentralCrossRef
113.
Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349–53.PubMedCrossRef
114.
Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL Jr, Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012;131(1):41–8.PubMedCrossRef
115.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol. 2017;3(4):509–15.PubMedCrossRef
116.
Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014;14:147.PubMedPubMedCentralCrossRef
117.
Zhu Y, Li Q, Gao J, He Z, Sun R, Shen G, et al. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy. Breast J. 2013;19(4):382–7.PubMedCrossRef
118.
Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol. 2018;31(1):68–82.PubMedCrossRef
119.
Roininen N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, Mattson J, Heikkila P, et al. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. BMC Cancer. 2017;17(1):72.PubMedPubMedCentralCrossRef
120.
Yildirim Y, Elagoz S, Koyuncu A, Aydin C, Karadayi K. Management of neuroendocrine carcinomas of the breast: a rare entity. Oncol Lett. 2011;2(5):887–90.PubMedPubMedCentral
121.
Cui ZQ, Feng JH, Zhao YJ. Clinicopathological features of invasive micropapillary carcinoma of the breast. Oncol Lett. 2015;9(3):1163–6.PubMedCrossRef
122.
Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004;121(6):857–66.PubMedCrossRef
123.
Yun SU, Choi BB, Shu KS, Kim SM, Seo YD, Lee JS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer. 2012;15(1):57–64.PubMedPubMedCentralCrossRef
124.
Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 2008;215(4):398–410.PubMedCrossRef
125.
Dieci MV, Smutna V, Scott V, Yin G, Xu R, Vielh P, et al. Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat. 2016;156(1):21–32.PubMedCrossRef
126.
Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol. 2006;126(5):740–6.PubMedCrossRef
127.
Yoon GY, Cha JH, Kim HH, Shin HJ, Chae EY, Choi WJ. Comparison of invasive micropapillary and invasive ductal carcinoma of the breast: a matched cohort study. Acta Radiol. 2019;60(11):1405–13.PubMedCrossRef
128.
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. 2013;13(2):133–9.PubMedCrossRef
129.
Liu Y, Huang X, Bi R, Yang W, Shao Z. Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China. PLoS One. 2014;9(9):e106564.PubMedPubMedCentralCrossRef
130.
Yang YL, Liu BB, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: an update. Arch Pathol Lab Med. 2016;140(8):799–805.PubMedCrossRef
131.
Ye F, Yu P, Li N, Yang A, Xie X, Tang H, et al. Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: a meta-analysis of PSM studies. Breast. 2020;51:11–20.PubMedPubMedCentralCrossRef
132.
• Aboumrad MH, Horn RC Jr, Fine G. Lipid-secreting mammary carcinoma. Report of a case associated with Paget's disease of the nipple. Cancer. 1963;16:521–5 This work first defined lipid rich carcinoma of the breast.PubMedCrossRef
133.
F.A. T, PE D, editors. World Health Organization classification of tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon, France: IARC Press; 2003.
134.
Kini H, Bhat S, Suresh PK, Thomas M. Clear cell carcinoma of breast lipid-rich variant. J Cancer Res Ther. 2019;15(5):1167–9.PubMedCrossRef
135.
Oba T, Ono M, Iesato A, Hanamura T, Watanabe T, Ito T, et al. Lipid-rich carcinoma of the breast that is strongly positive for estrogen receptor: a case report and literature review. Onco Targets Ther. 2016;9:1641–6.PubMedPubMedCentral
136.
Shi P, Wang M, Zhang Q, Sun J. Lipid-rich carcinoma of the breast. A clinicopathological study of 49 cases. Tumori. 2008;94(3):342–6.PubMedCrossRef
137.
Cong Y, Lin J, Qiao G, Zou H, Wang X, Li X, et al. Lipid-rich carcinoma of the breast: a report of two cases and a literature review. Oncol Lett. 2015;9(4):1729–32.PubMedPubMedCentralCrossRef
138.
Guan B, Wang H, Cao S, Rao Q, Wang Y, Zhu Y, et al. Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases. Ann Diagn Pathol. 2011;15(4):225–32.PubMedCrossRef
139.
Umekita Y, Yoshida A, Sagara Y, Yoshida H. Lipid-secreting carcinoma of the breast: a case report and review of the literature. Breast Cancer. 1998;5(2):171–3.PubMedCrossRef
140.
Damiani S, Eusebi V, Losi L, D'Adda T, Rosai J. Oncocytic carcinoma (malignant oncocytoma) of the breast. Am J Surg Pathol. 1998;22(2):221–30.PubMedCrossRef
141.
Itagaki H, Yamamoto T, Hiroi A, Kawanishi K, Noguchi E, Ohchi T, et al. Synchronous and bilateral oncocytic carcinoma of the breast: a case report and review of the literature. Oncol Lett. 2017;13(3):1714–8.PubMedPubMedCentralCrossRef
142.
Ragazzi M, de Biase D, Betts CM, Farnedi A, Ramadan SS, Tallini G, et al. Oncocytic carcinoma of the breast: frequency, morphology and follow-up. Hum Pathol. 2011;42(2):166–75.PubMedCrossRef
143.
Costa MJ, Silverberg SG. Oncocytic carcinoma of the male breast. Arch Pathol Lab Med. 1989;113(12):1396–9.PubMed
144.
Marla NJ, Pai MR, Swethadri GK, Fernandes H. Male breast cancer-review of literature on a rare microscopic variant (oncocytic carcinoma). Indian J Surg. 2013;75(Suppl 1):240–2.PubMedCrossRef
145.
Heng C, Wei T, Yingbing T, Hanzhong L. Clinicopathological characteristics of breast sebaceous adenocarcinoma. Pol J Pathol. 2018;69(3):226–33.PubMedCrossRef
146.
van Bogaert LJ, Maldague P. Histologic variants of lipid-secreting carcinoma of the breast. Virchows Arch A Pathol Anat Histol. 1977;375(4):345–53.PubMedCrossRef
147.
Maia T, Amendoeira I. Breast sebaceous carcinoma-a rare entity. Clinico-pathological description of two cases and brief review. Virchows Arch. 2018;472(5):877–80.PubMedCrossRef
148.
Acosta AM, Al Rasheed MRH, Xu H, Salibay C, Pins MR. Sebaceous carcinoma of the breast in a patient with a pathogenic BRCA2 (886delGT) mutation - focus on histopathologic and immunohistochemical features. APMIS. 2018;126(4):353–6.PubMedCrossRef
149.
Kyriakos Saad M, Ghandour F, El Hachem G, Ghandour-Hajj F, El Hajj I, Saikaly E. Special type breast carcinoma: sebaceous carcinoma of the breast; A case report and review of literature. Breast J. 2020;26:2034–7.PubMedCrossRef
150.
Eun NL, Cha YJ, Son EJ, Gweon HM, Kim JA, Youk JH. Clinical imaging of glycogen-rich clear cell carcinoma of the breast: a case series with literature review. Magn Reson Med Sci. 2019;18(3):238–42.PubMedCrossRef
151.
Zhou Z, Kinslow CJ, Hibshoosh H, Guo H, Cheng SK, He C, et al. Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. population. J Clin Med. 2019;8(2).
152.
Koenig C, Tavassoli FA. Mucinous cystadenocarcinoma of the breast. Am J Surg Pathol. 1998;22(6):698–703.PubMedCrossRef
153.
Koufopoulos N, Goudeli C, Syrios J, Filopoulos E, Khaldi L. Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. Rare Tumors. 2017;9(3):7016.PubMedPubMedCentralCrossRef
154.
Kucukzeybek BB, Yigit S, Sari AA, Rezanko T, Durak E, Sadullahoglu C. Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature. Pol J Pathol. 2014;65(1):70–3.PubMedCrossRef
155.
Petersson F, Pang B, Thamboo TP, Putti TC. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: the first case reported. Hum Pathol. 2010;41(6):910–3.PubMedCrossRef
Metadaten
Titel
Rare Breast Cancer Subtypes
verfasst von
Sarah Jenkins
Megan E. Kachur
Kamil Rechache
Justin M. Wells
Stanley Lipkowitz
Publikationsdatum
01.05.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 5/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01048-4

Weitere Artikel der Ausgabe 5/2021

Current Oncology Reports 5/2021 Zur Ausgabe

Breast Cancer (AS Zimmer, Section Editor)

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Breast Cancer (AS Zimmer, Section Editor)

Role of Platinums in Triple-Negative Breast Cancer

Pediatric Oncology (KL Davis, Section Editor)

Childhood Acute Leukemias in Developing Nations: Successes and Challenges

Neuroendocrine Neoplasms (NS Reed, Section Editor)

The Role of Patient Support Groups in Neuroendocrine Neoplasms

Breast Cancer (AS Zimmer, Section Editor)

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Breast Cancer (AS Zimmer, Section Editor)

Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise